Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis
Dispose of any leftover water responsibly
In this population, 53% of individuals had commercial health insurance, 18% had Medicare, 11% had Medicaid, 1% had Dual (Medicare/Medicaid) coverage, and 17% had other coverage (e.g., Tricare, Veterans Affairs, or other State or local programs)
To learn how Celtarys can empower your next GLP1 drug discovery project, contact our scientific support team today
Clinical data from SURMOUNT trials showed tirzepatide produced 20-22% weight loss over 68 weeks in non-surgical populations